ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,842,881 | -11.2% | 184,400 | +2.0% | 0.00% | -20.0% |
| Q2 2023 | $4,329,585 | +132262.7% | 180,776 | +4.0% | 0.01% | +25.0% |
| Q1 2023 | $3,271 | +18.9% | 173,799 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $2,752 | -99.9% | 172,882 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $2,741,000 | +28.8% | 167,560 | +11.0% | 0.00% | +33.3% |
| Q2 2022 | $2,128,000 | -34.2% | 151,015 | +13.2% | 0.00% | -25.0% |
| Q1 2022 | $3,232,000 | +7.8% | 133,444 | +3.9% | 0.00% | 0.0% |
| Q4 2021 | $2,998,000 | +38.7% | 128,433 | -1.3% | 0.00% | +33.3% |
| Q3 2021 | $2,162,000 | -31.0% | 130,173 | +1.3% | 0.00% | -25.0% |
| Q2 2021 | $3,135,000 | +5.0% | 128,522 | +11.1% | 0.00% | 0.0% |
| Q1 2021 | $2,985,000 | -55.3% | 115,682 | -7.3% | 0.00% | -55.6% |
| Q4 2020 | $6,672,000 | +29.7% | 124,796 | +0.1% | 0.01% | +12.5% |
| Q3 2020 | $5,144,000 | -19.7% | 124,696 | -5.7% | 0.01% | -27.3% |
| Q2 2020 | $6,408,000 | -6.7% | 132,211 | -18.7% | 0.01% | -21.4% |
| Q1 2020 | $6,867,000 | -0.2% | 162,535 | +1.1% | 0.01% | +16.7% |
| Q4 2019 | $6,878,000 | +29.9% | 160,777 | +9.3% | 0.01% | +20.0% |
| Q3 2019 | $5,293,000 | +31.5% | 147,068 | -2.3% | 0.01% | +25.0% |
| Q2 2019 | $4,024,000 | -0.1% | 150,530 | +0.3% | 0.01% | 0.0% |
| Q1 2019 | $4,029,000 | +87.6% | 150,068 | +13.0% | 0.01% | +60.0% |
| Q4 2018 | $2,148,000 | +17.2% | 132,816 | +50.4% | 0.01% | +25.0% |
| Q3 2018 | $1,833,000 | +27.3% | 88,303 | -6.4% | 0.00% | +33.3% |
| Q2 2018 | $1,440,000 | -37.3% | 94,318 | -7.7% | 0.00% | -40.0% |
| Q1 2018 | $2,297,000 | -29.6% | 102,228 | -5.7% | 0.01% | -28.6% |
| Q4 2017 | $3,263,000 | -22.0% | 108,360 | -2.5% | 0.01% | -22.2% |
| Q3 2017 | $4,185,000 | +29.6% | 111,094 | -4.0% | 0.01% | +28.6% |
| Q2 2017 | $3,229,000 | -20.0% | 115,776 | -1.3% | 0.01% | -22.2% |
| Q1 2017 | $4,034,000 | +18.9% | 117,349 | -0.3% | 0.01% | 0.0% |
| Q4 2016 | $3,394,000 | -1.8% | 117,689 | +8.3% | 0.01% | -10.0% |
| Q3 2016 | $3,457,000 | +7.5% | 108,683 | +9.7% | 0.01% | 0.0% |
| Q2 2016 | $3,215,000 | +42.3% | 99,030 | +22.5% | 0.01% | +42.9% |
| Q1 2016 | $2,260,000 | -15.1% | 80,840 | +8.2% | 0.01% | -22.2% |
| Q4 2015 | $2,663,000 | +10.4% | 74,690 | +2.4% | 0.01% | +12.5% |
| Q3 2015 | $2,413,000 | -19.4% | 72,975 | +2.1% | 0.01% | -20.0% |
| Q2 2015 | $2,992,000 | +23.6% | 71,453 | -3.8% | 0.01% | +42.9% |
| Q1 2015 | $2,420,000 | +21.8% | 74,253 | +18.7% | 0.01% | +16.7% |
| Q4 2014 | $1,987,000 | +27.0% | 62,568 | -0.9% | 0.01% | +20.0% |
| Q3 2014 | $1,564,000 | +3.0% | 63,163 | -6.1% | 0.01% | +25.0% |
| Q2 2014 | $1,519,000 | +0.3% | 67,253 | +8.0% | 0.00% | 0.0% |
| Q1 2014 | $1,515,000 | -7.5% | 62,257 | -4.9% | 0.00% | -20.0% |
| Q4 2013 | $1,637,000 | -4.2% | 65,497 | +5.3% | 0.01% | 0.0% |
| Q3 2013 | $1,709,000 | +76.4% | 62,227 | +16.5% | 0.01% | +66.7% |
| Q2 2013 | $969,000 | – | 53,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |